Document Detail

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
MedLine Citation:
PMID:  24161018     Owner:  NLM     Status:  Publisher    
Background: The Raltegravir Switch for Toxicity or Adverse Events (RASTA) Study is a 2-arm randomized pilot study exploring the safety and efficacy at 48 weeks of a treatment switch to raltegravir associated with tenofovir/emtricitabine or abacavir/lamivudine in patients with regimens with optimal virological control. Methods: Patients treated with stable protease inhibitor (PI)-, non-nucleoside reverse transcriptase inhibitor (NNRTI)-, or nucleoside reverse transcriptase inhibitor (NRTI)-based regimens, with HIV-RNA levels < 50 copies/ml for ≥ 3 months and a CD4 cell count > 200 cells/μl were eligible. Enrollment of 40 patients was planned: at baseline patients were randomized 1:1 to switch to raltegravir plus tenofovir/emtricitabine (arm A) or abacavir/lamivudine (arm B). Laboratory parameters, raltegravir plasma levels, self- reported adherence, quality of life parameters, neurocognitive performance, bone composition, and body fat distribution were monitored. Virological failure was defined as HIV-RNA > 50 copies/ml on 2 consecutive determinations. Results: After 48 weeks, 5/40 (12.5%) regimen discontinuations occurred: 2 were for low-level viremia virological failure (both in arm A, at weeks 24 and 48) and 3 were for adverse events (neurological disturbances and skin rash in arm B; proximal tubulopathy in arm A). Overall, a significant CD4 increase was observed at weeks 36 and 48, and a significant decrease in total cholesterol, non-high density lipoprotein cholesterol, and triglycerides was observed at each study visit. Physical health/satisfaction in therapy scores and neuropsychological performance improved. The lumbar column Z-score improved, with no modification in other bone composition and fat distribution parameters. Conclusions: The investigated switch strategy was associated with rare virological failure. Improvements in lipid levels, quality of life measures, neuropsychological performance, and bone composition suggest good tolerability of raltegravir-based regimens.
Massimiliano Fabbiani; Annalisa Mondi; Manuela Colafigli; Gabriella D'Ettorre; Francesca Paoletti; Alessandro D'Avino; Nicoletta Ciccarelli; Letizia Sidella; Rita Murri; Serena Fortuna; Vincenzo Vullo; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto
Related Documents :
23370838 - Catheters: a guide to selecting appropriate products.
7013508 - Sphincterotomy or sphincteroplasty in the treatment of pathologically mild chronic panc...
24562938 - Long-term clinical and functional results of intersphincteric resection for lower recta...
24378548 - Quality of life after surgical treatment of early barrett's cancer: a prospective compa...
16388958 - Left ventricular reconstruction benefits patients with ischemic cardiomyopathy and non-...
15963128 - A prospective randomized trial comparing transurethral prostatic resection and clean in...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-10-28
Journal Detail:
Title:  Scandinavian journal of infectious diseases     Volume:  -     ISSN:  1651-1980     ISO Abbreviation:  Scand. J. Infect. Dis.     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-10-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0215333     Medline TA:  Scand J Infect Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart , Rome.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol...
Next Document:  Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.